You Have the Power to Take Action

Size: px

Start display at page:

Download "You Have the Power to Take Action"

Lucinda Warner
6 years ago
Views:

LARTRUVO + DOXORUBICIN FOR SOFT TISSUE SARCOMA You Have the Power to Take Action A soft tissue sarcoma diagnosis can be a shock. Understanding your treatment can make a difference.

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who

SELECT IMPORTANT SAFETY INFORMATION Ǵ Ǵ Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion.

1 LARTRUVO + DOXORUBICIN FOR SOFT TISSUE SARCOMA You Have the Power to Take Action A soft tissue sarcoma diagnosis can be a shock. Understanding your treatment can make a difference. WHO IS LARTRUVO FOR? LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery. There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin. SELECT IMPORTANT SAFETY INFORMATION Ǵ Ǵ Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/ chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially lifethreatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

WHAT IS SOFT TISSUE SARCOMA? Soft tissue sarcoma is a cancer that begins in the soft tissues of the body. This can include the muscles, tendons, fat, blood vessels, or other supporting tissue.

2 WHAT IS SOFT TISSUE SARCOMA? Soft tissue sarcoma is a cancer that begins in the soft tissues of the body. This can include the muscles, tendons, fat, blood vessels, or other supporting tissue. Nerves Blood Vessels Fat Understanding Your Diagnosis Soft tissue sarcoma is considered a rare cancer. Every year approximately 12,000 PEOPLE are diagnosed with soft tissue sarcoma in the U.S. Muscles, Tendons, Ligaments, and Cartilage BE STRONG Because you are not your diagnosis TYPES OF SOFT TISSUE SARCOMA There are many different types of soft tissue sarcoma, which are called subtypes. According to the American Cancer Society, there are more than 50 DIFFERENT SUBTYPES. Different subtypes of soft tissue sarcoma are usually associated with certain locations in the body and types of tissue. Common types of soft tissue sarcoma in adults include undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma. 3

3 LARTRUVO + DOXORUBICIN THE FIRST FRONT-LINE ADVANCEMENT IN SOFT TISSUE SARCOMA IN MORE THAN 40 YEARS WHO IS LARTRUVO FOR? LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery. There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin. SELECT IMPORTANT SAFETY INFORMATION Ǵ Ǵ LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO. BE STRONG Because you re still you 4

4 WHO IS LARTRUVO FOR? LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery. There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin. HOW LARTRUVO WORKS LARTRUVO works differently than a chemotherapy. It is a monoclonal antibody, a type of biologic therapy that works to mimic part of your body s own immune system. LARTRUVO binds to certain substances and blocks cells from sending growth signals to cancer cells, as well as other healthy cells. IS LARTRUVO RIGHT FOR ME? LARTRUVO has been shown to be effective for adult patients with soft tissue sarcoma when used with doxorubicin. It was studied in multiple subtypes of soft tissue sarcoma.* Talk to your healthcare team if you have questions regarding your specific subtype. *Specific clinical benefits for each subtype have not been established. Learn more about the benefits and safety information of LARTRUVO + doxorubicin from a study of people with soft tissue sarcoma. Visit BIOLOGIC THERAPY: A type of treatment that uses substances made from living organisms to treat disease. SELECT IMPORTANT SAFETY INFORMATION Ǵ Ǵ The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache. 7

5 HOW LARTRUVO IS GIVEN BE STRONG Because you have the power to take action 8

HOW IS LARTRUVO GIVEN? LARTRUVO is an IV infusion given by a healthcare professional in a doctor's office, hospital, or infusion center. You may be at the infusion center for a total of 2 to 3 hours.

6 HOW IS LARTRUVO GIVEN? LARTRUVO is an IV infusion given by a healthcare professional in a doctor's office, hospital, or infusion center. You may be at the infusion center for a total of 2 to 3 hours. Your treatment will be scheduled in cycles. There are 3 weeks (21 days) in each treatment cycle. You will be given treatment on Days 1 and 8 of each 3-week (21-day) cycle. Treatment Day Treatment Day No Treatment 2 DAYS OF TREATMENT PER 21-DAY CYCLE On the 1st day of treatment, you will receive both LARTRUVO and doxorubicin. On the 8th day, you will receive LARTRUVO only On Day 1 of each treatment cycle, you will receive 1 hour of LARTRUVO followed by 1 hour or less of doxorubicin. You will receive medications before your LARTRUVO infusion. This will help prepare your body for treatment with LARTRUVO. LARTRUVO doxorubicin No treatment Get helpful tips on starting treatment, including ways to prepare for your first infusion. Visit HOW LONG WILL I RECEIVE TREATMENT? Your healthcare team will decide the appropriate length of treatment. Your treatment plan may include LARTRUVO and doxorubicin for up to 8 cycles of treatment. After the 8th cycle, your healthcare team may decide to continue treatment with LARTRUVO alone. This will depend on the progress of your disease and how your body responds to therapy. If your medicine changes, it may also affect the side effects you experience. If your disease progresses, your doctor will end treatment with LARTRUVO and discuss with you the appropriate next steps for your treatment plan. SELECT IMPORTANT SAFETY INFORMATION Ǵ Ǵ The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level. 11

7 SIDE EFFECTS OF LARTRUVO HAVE A QUESTION? If you experience serious side effects at any point during treatment, your doctor may end, delay, or modify your treatment plan. This is not a full list of side effects. THE MOST COMMON SIDE EFFECTS OF LARTRUVO INCLUDE: Nausea Tiredness or weakness Pain in the muscles, joints, and bones Sores and swelling of the mouth and digestive tract Hair loss Vomiting Diarrhea Decreased appetite Stomach pain Weakness, numbness, or pain in the hands and feet Headache Ǵ Ǵ You probably have questions about your treatment with LARTRUVO. Always talk with your doctor first if you have any questions or if you are seeking medical advice. Your personal healthcare team is the best source of information about your health Ǵ Ǵ If you have any questions about LARTRUVO, you can give us a call at The Lilly Answers Center: LILLYRX ( ) By calling this number, you will have access to a Lilly representative who can provide additional information. The toll-free number is a service provided by Eli Lilly and Company and is not intended to replace the advice of your healthcare team Ǵ Ǵ If you have a medical emergency, immediately call 911 or your local emergency services number Talk to your healthcare team if you notice any side effects, including any signs of fever. If you have any questions about LARTRUVO, you can give us a call at The Lilly Answers Center: LILLYRX ( ). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/safety/medwatch or call FDA

8 IMPORTANT SAFETY INFORMATION WHO IS LARTRUVO FOR? LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery. There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin. IMPORTANT SAFETY INFORMATION What is the most important information I should know about LARTRUVO? Ǵ Ǵ Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped. Ǵ Ǵ LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO. What are the most common side effects of LARTRUVO? ǴThe Ǵ most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache. Ǵ Ǵ The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call FDA What should I tell my doctor before receiving treatment with LARTRUVO? Before you receive LARTRUVO, tell your doctor if you: Ǵ Ǵ Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor. Ǵ Ǵ Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO. Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications. LARTRUVO is available by prescription only. Please see full Prescribing Information for additional OR CON ISI 12JAN

Lilly PatientOne strives to offer reliable and individualized treatment support for eligible patients prescribed a Lilly Oncology product whether they are insured, underinsured, or simply uninsured.

9 Lilly PatientOne strives to offer reliable and individualized treatment support for eligible patients prescribed a Lilly Oncology product whether they are insured, underinsured, or simply uninsured. Co-pay Program* No income eligibility requirement Provides an annual maximum patient benefit of $25,000 For more information, visit * This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program. Reimbursement Assistance Evaluates financial assistance options including co-pay programs and independent patient assistance foundations Provides reimbursement assistance (eligibility determination, benefits investigation, prior authorization assistance, denied claims appeals information) Lilly Cares Foundation The Lilly Cares Foundation, Inc, a separate nonprofit organization, provides free Lilly medications to qualifying patients. For more information about Lilly Cares, please visit LillyCares.com or call For more information about Lilly PatientOne, call PatOne ( ), Monday Friday, 9 AM 7 PM ET, or visit LillyPatientOne.com. PP-OR-US /2018 Lilly USA, LLC All rights reserved. LARTRUVO TM is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

BILLING AND CODING GUIDE

BILLING AND CODING GUIDE The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations, and policies concerning